Compare Sun Pharma with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs VENUS REMEDIES - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA VENUS REMEDIES SUN PHARMA/
VENUS REMEDIES
 
P/E (TTM) x 21.2 -1.1 - View Chart
P/BV x 2.5 0.1 3,372.9% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 SUN PHARMA   VENUS REMEDIES
EQUITY SHARE DATA
    SUN PHARMA
Mar-19
VENUS REMEDIES
Mar-18
SUN PHARMA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs679126 539.2%   
Low Rs37561 614.4%   
Sales per share (Unadj.) Rs121.1301.8 40.1%  
Earnings per share (Unadj.) Rs13.4-24.9 -53.8%  
Cash flow per share (Unadj.) Rs20.72.5 812.9%  
Dividends per share (Unadj.) Rs2.750-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs172.6293.3 58.8%  
Shares outstanding (eoy) m2,399.2612.34 19,442.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.40.3 1,404.4%   
Avg P/E ratio x39.4-3.8 -1,048.2%  
P/CF ratio (eoy) x25.536.7 69.4%  
Price / Book Value ratio x3.10.3 958.0%  
Dividend payout %20.60-   
Avg Mkt Cap Rs m1,264,6501,154 109,608.3%   
No. of employees `00017.50.9 1,892.0%   
Total wages/salary Rs m59,671393 15,179.6%   
Avg. sales/employee Rs Th16,608.14,026.1 412.5%   
Avg. wages/employee Rs Th3,409.6425.0 802.3%   
Avg. net profit/employee Rs Th1,833.8-331.8 -552.7%   
INCOME DATA
Net Sales Rs m290,6593,724 7,804.8%  
Other income Rs m10,25523 45,577.3%   
Total revenues Rs m300,9143,747 8,031.7%   
Gross profit Rs m63,076395 15,976.7%  
Depreciation Rs m17,533338 5,182.5%   
Interest Rs m5,553354 1,567.2%   
Profit before tax Rs m50,246-275 -18,251.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-12,1440-   
Tax Rs m6,00932 19,015.2%   
Profit after tax Rs m32,093-307 -10,457.2%  
Gross profit margin %21.710.6 204.7%  
Effective tax rate %12.0-11.5 -104.2%   
Net profit margin %11.0-8.2 -134.0%  
BALANCE SHEET DATA
Current assets Rs m310,6922,638 11,779.0%   
Current liabilities Rs m173,3962,305 7,523.8%   
Net working cap to sales %47.28.9 528.2%  
Current ratio x1.81.1 156.6%  
Inventory Days Days99135 73.1%  
Debtors Days Days11246 240.8%  
Net fixed assets Rs m232,4774,871 4,772.9%   
Share capital Rs m2,399123 1,944.3%   
"Free" reserves Rs m411,6913,496 11,777.2%   
Net worth Rs m414,0913,619 11,441.8%   
Long term debt Rs m15,2261,374 1,107.8%   
Total assets Rs m646,9387,509 8,616.1%  
Interest coverage x10.00.2 4,506.9%   
Debt to equity ratio x00.4 9.7%  
Sales to assets ratio x0.40.5 90.6%   
Return on assets %5.80.6 921.8%  
Return on equity %7.8-8.5 -91.4%  
Return on capital %10.21.6 642.7%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m66,0250-   
Fx outflow Rs m38,610517 7,475.4%   
Net fx Rs m27,415-517 -5,307.9%   
CASH FLOW
From Operations Rs m21,965514 4,269.9%  
From Investments Rs m-6,813-123 5,534.1%  
From Financial Activity Rs m-27,305-387 7,053.8%  
Net Cashflow Rs m-8,4424 -200,988.1%  

Share Holding

Indian Promoters % 63.7 32.9 193.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 0.2 2,850.0%  
FIIs % 23.0 0.6 3,965.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 66.4 12.5%  
Shareholders   133,026 20,121 661.1%  
Pledged promoter(s) holding % 0.5 36.4 1.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   DR. DATSONS LABS  DISHMAN PHARMA  J.B.CHEMICALS  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Momentum; Sensex Trades 186 Points Higher(12:30 pm)

Share markets in India are presently trading on a strong note. Sectoral indices are trading on a mixed note with stocks in the telecom sector.

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Nov 19, 2019 01:23 PM

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS